ClinicalTrials.gg
CompletedNCT014043254EVERLUNGUpdated Mar 14, 2019Results posted

Efficacy Regarding Renal Function of Everolimus in Combination With Specific Standard Immunosuppressive Regimen Lung Transplant Recipients

A Phase 3 interventional study of standard therapy and Everolimus in Lung Transplantation, sponsored by Novartis Pharmaceuticals. Completed at 9 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-14.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This trial evaluated the efficacy of an everolimus-based quadruple low immunosuppressive regimen versus a standard immunosuppressive regimen concerning kidney function in lung transplant recipients.

02

Conditions studied

  • Lung Transplantation

Keywords

  • Lung transplantation
  • everolimus
  • kidney function
  • renal function
03

In context

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult recipients of de novo cadaveric lung transplants 3-18 months prior to enrollment

Exclusion criteria

Exclusion criteria:

  • Patients with thrombocytopenia ( \<100,000/mm³), with an of \<1,500/mm³ or leucopenia (leucocytes \<3000/mm³), with anemia with \< 8g/dl at time of screening
  • Patients with uncontrolled hypercholesterolemia (> 350 mg/dL; > 9.1 mmol/L) or hypertriglyceridemia (> 750 mg/dL; > 8.5 mmol/L) at time of screening
  • Patients with a history of of any organ system, treated or untreated, during the last five years, whether or not there is evidence of local recurrence or , except squamous or basal cell carcinoma of the skin Other protocol-defined inclusion/exclusion criteria may apply
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
130 participants (actual)

Study arms

  • Experimental
    Quadruple low level IS regimen

    quadruple immunosuppressive (IS) regimen consisting of everolimus, CNI, MPA and steroids

    Drug: Everolimus

  • Experimental
    Centre specific triple IS regimen

    centre specific CNI-based triple drug immunosuppression (IS)

    Drug: standard therapy

Interventions

  • Drugstandard therapy

    centre specific CNI-based triple drug immunosuppression

  • quadruple immunosuppressive regimen consisting of everolimus, CNI, MPA and steroids

    Also known as: RAD001

06

What researchers measure

Primary outcomes

  1. Calculated Glomerular Filtration Rate (cGFR) According to Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) at 12 Months

    Calculated Glomerular Filtration Rate (cGFR) according to Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) at 12 months The CKD-EPI equation, expressed as a single equation, is GFR = 141 × min(Scr/κ, 1)α × max(Scr/κ, 1)\^-1.209 × 0.993Age × 1.018 (if female) × 1.159 (if black), where Scr is serum creatinine, κ is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates the minimum of Scr/ĸ or 1, and max indicates the maximum of Scr/κ or 1

    Time frame: Month 12

Secondary outcomes

  1. Calculated Glomerular Filtration Rate (cGFR) According to Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) at Month 1, 3, 6, 9, 12

    Calculated Glomerular Filtration Rate (cGFR) according to Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) at Month 1, 3, 6, 9 and 12. The CKD-EPI equation, expressed as a single equation, is GFR = 141 × min(Scr/κ, 1)α × max(Scr/κ, 1)\^-1.209 × 0.993Age × 1.018 (if female) × 1.159 (if black), where Scr is serum creatinine, κ is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates the minimum of Scr/ĸ or 1, and max indicates the maximum of Scr/κ or 1

    Time frame: Month 1, 3, 6, 9, 12

  2. Calculated Glomerular Filtration Rate (cGFR) According to Cystatin C-based Hoek's Formula at Month 1, 3, 6, 9, 12

    Calculated Glomerular Filtration Rate (cGFR) according to Cystatin C-based Hoek's formula at Month 1, 3, 6, 9, 12

    Time frame: Month 1, 3, 6, 9, 12

  3. Calculated Glomerular Filtration Rate (cGFR) Using Modification of Diet in Renal Disease (MDRD) Formula at Month 1, 3, 6, 9, 12

    Calculated Glomerular Filtration Rate (cGFR) Using Modification of Diet in Renal Disease (MDRD) Formula at Month 1, 3, 6, 9, 12 cGFR (in mL/min/1.73 m2) = 186.3\*(C-1.154)\*(A-0.203)\*G\*R where C = the serum concentration of creatinine (mg/dL), A = age (years), G = 0.742 when gender is female, otherwise G = 1, R = 1.21 when race is black, otherwise R = 1.

    Time frame: Month 1, 3, 6, 9, 12

  4. Calculated Glomerular Filtration Rate (cGFR) According to Cockcroft-Gault at Month 1, 3, 6, 9, 12

    Calculated Glomerular Filtration Rate (cGFR) according to Cockcroft-Gault at Month 1, 3, 6, 9, 12 For men: GFR=(140-Age) x Body weight (kg) / 72 x Serum Creatinine (mg/dl) For women: GFR=0.85 (140 -Age) x Body weight(kg)/ 72 x Serum Creatinine (mg/dl)

    Time frame: Month 1, 3, 6, 9, 12

  5. Incidence of Patients Experiencing a Decline in GFR of < 10, 10-15, 15-20, 20-25 and > 25 mL/Min From Baseline to Month 6 and 12.

    Incidence of patients experiencing a decline in GFR of \< 10, 10-15, 15-20, 20-25 and \> 25 mL/min from Baseline to Month 6 and 12calculated by the CKD-EPI method. Participants are counted in each decline level observed for that participant; this means participants may be counted in more than 1 decline level.

    Time frame: Baseline, Month 6, Month 12

  6. Incidence of Renal Replacement Therapy at Month 6 and Month 12

    Incidence of renal replacement therapy at Month 6 and Month 12: There were no incidences in either group where renal replacement therapy was required

    Time frame: Month 6, Month 12

  7. Time to Renal Replacement Therapy at Month 6 and Month 12

    Time to renal replacement therapy at Month 6 and Month 12: There were no incidences in either group where renal replacement therapy was required

    Time frame: Month 6, Month 12

  8. Incidence of Acute Rejection Episodes at Month 6 and Month 12

    Incidence of acute rejection episodes at Month 6 and Month 12. This table counts multiple occurrences of rejection in the same patient as different incidents. Every incident is associated with both an A and a B classification. Classification A: Acute Rejection Grade 0 - none, Grade 1-minimal, Grade 2- mild, Grade 3-moderate, Grade 4-Severe; Classification B: Airway Inflammation-Grade 0-none, Grade 1R-low grade, Grade 2R-high grade, Grade X-ungradeable

    Time frame: Month 6, Month 12

  9. Incidence of Graft Loss/Re-transplantation at Month 6 and Month 12

    Incidence of graft loss/re-transplantation at Month 6 and Month 12

    Time frame: Month 6, Month 12

  10. Incidence of Bronchiolitis Obliterans Syndrome (BOS) at Month 6 and Month 12

    Incidence of Bronchiolitis obliterans syndrome (BOS) at Month 6 and Month 12 BOS 0 is FEV1 \> 90% of baseline and FEF25-75% \> 75% of baseline; BOS 0-p is FEV1 81-90% of baseline and/or FEF25-75% ≤ 75% of baseline; BOS 1 is FEV1 66-80% of baseline; BOS 2 is FEV1 51-65% of baseline; BOS 3 is FEV1 ≤ 50% of baseline

    Time frame: Month 6, Month 12

  11. Incidence of Death at Month 6 and Month 12

    Incidence of death at Month 6 and Month 12

    Time frame: Month 6, Month 12

  12. Quality of Life (QoL, SF36) at Month 6 and Month 12

    Quality of Life (QoL, SF36) at Month 6 and Month 12 Scores can range from a minimum of 0 (maximum disability) to a maximum of 100 (no disability).

    Time frame: Month 6, Month 12

  13. Exercise Capacity 6-Minute Walk Test(6MWT) at Month 6 and Month 12

    Exercise capacity (6MWT) at Month 6 and Month 12 Measured by the Borg Scale. THE BORG SCALE 0 is Nothing at all, 0.5 is Very, very slight (just noticeable); 1 is Very slight, 2 is Slight (light); 3 is Moderate; 4 is Somewhat severe; 5 is Severe (heavy), 7 is Very severe, 10 is Very, very severe (maximal)The higher the Borg score implies increased shortness of breath and/or increased fatigue.

    Time frame: Month 6, Month 12

  14. Incidence of Treated Arterial Hypertension up to Month 12

    Incidence of treated of arterial hypertension up to Month 12

    Time frame: up to Month 12

  15. Incidence of Diabetes Mellitus up to Month 12

    Incidence of Diabetes Mellitus up to Month 12

    Time frame: up to Month 12

  16. Trough Levels of Everolimus at Month 1, 3, 6, 9, 12

    Trough levels of everolimus at Month 1, 3, 6, 9, 12

    Time frame: Month 1, 3, 6, 9, 12

  17. Adherence to Target Ranges of Everolimus at Month 1, 3, 6, 9, 12

    Adherence to target ranges of everolimus at Month 1, 3, 6, 9, 12

    Time frame: Month 1, 3, 6, 9, 12

  18. Trough Levels of Cyclosporine A (CsA) at Month 1, 3, 6, 9, 12

    Trough levels of Cyclosporine A (CsA) at Month 1, 3, 6, 9, 12

    Time frame: Month 1, 3, 6, 9, 12

  19. Adherence to Target Ranges of Cyclosporine A (CsA) at Month 1, 3, 6, 9, 12

    Adherence to target ranges of Cyclosporine A (CsA) at Month 1, 3, 6, 9, 12

    Time frame: Month 1, 3, 6, 9, 12

  20. Trough Levels of Tacrolimus at Month 1, 3, 6, 9, 12

    Trough levels of Tacrolimus at Month 1, 3, 6, 9, 12

    Time frame: Month 1, 3, 6, 9, 12

  21. Adherence to Target Ranges of Tacrolimus at Month 1, 3, 6, 9, 12

    Adherence to target ranges of Tacrolimus at Month 1, 3, 6, 9, 12

    Time frame: Month 1, 3, 6, 9, 12

  22. Incidence of Bacterial, Viral, and Fungal Infections at Month 12

    Incidence of bacterial, viral, and fungal infections at Month 12

    Time frame: Month 12

  23. Triglyceride Levels at Month 1, 3, 6, 9, 12

    Triglyceride levels at Month 1, 3, 6, 9, 12

    Time frame: Month 1, 3, 6, 9, 12

  24. Total Cholesterol Levels at Month 1, 3, 6, 9, 12

    Total Cholesterol levels at Month 1, 3, 6, 9, 12

    Time frame: Month 1, 3, 6, 9, 12

  25. Low-Density Lipoprotein (LDL)Cholesterol Levels at Month 1, 3, 6, 9, 12

    LDL Cholesterol levels at Month 1, 3, 6, 9, 12

    Time frame: Month 1, 3, 6, 9, 12

  26. High-Density Lipoprotein (HDL)Cholesterol Levels at Month 1, 3, 6, 9, 12

    HDL Cholesterol levels at Month 1, 3, 6, 9, 12

    Time frame: Month 1, 3, 6, 9, 12

07

Results

Posted Mar 14, 2019

Participant flow

232 patients who were de novo lung transplant recipients were planned for enrolling into the study. A total of 130 patients were actually randomized with 67 patients randomized to the quadruple low-level treatment arm and 63 patients randomized to the center-specific triple treatment arm.

Participant flow — Overall Study
MilestoneQuadruple Low Level IS RegimenCentre Specific Triple IS Regimen
Started6763
Completed6361
Not completed42
Withdrew: Lost to follow-up10
Withdrew: Death20
Withdrew: Graft loss/retransplantation10
Withdrew: Non-specified reason02

Outcome measures

PrimaryCalculated Glomerular Filtration Rate (cGFR) According to Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) at 12 Months

Calculated Glomerular Filtration Rate (cGFR) according to Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) at 12 months The CKD-EPI equation, expressed as a single equation, is GFR = 141 × min(Scr/κ, 1)α × max(Scr/κ, 1)\^-1.209 × 0.993Age × 1.018 (if female) × 1.159 (if black), where Scr is serum creatinine, κ is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates the minimum of Scr/ĸ or 1, and max indicates the maximum of Scr/κ or 1

Time frame:
Month 12
Reported as:
Least squares mean · mL/min
Calculated Glomerular Filtration Rate (cGFR) According to Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) at 12 Months
mL/minQuadruple Low Level IS RegimenCentre Specific Triple IS Regimen
Calculated Glomerular Filtration Rate (cGFR) According to Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) at 12 Months64.5 ± 16.354.6 ± 14.3
Statistical analysis
  • Quadruple Low Level IS Regimen vs Centre Specific Triple IS Regimen · ANCOVA · p = <0.0001
SecondaryCalculated Glomerular Filtration Rate (cGFR) According to Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) at Month 1, 3, 6, 9, 12

Calculated Glomerular Filtration Rate (cGFR) according to Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) at Month 1, 3, 6, 9 and 12. The CKD-EPI equation, expressed as a single equation, is GFR = 141 × min(Scr/κ, 1)α × max(Scr/κ, 1)\^-1.209 × 0.993Age × 1.018 (if female) × 1.159 (if black), where Scr is serum creatinine, κ is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates the minimum of Scr/ĸ or 1, and max indicates the maximum of Scr/κ or 1

Time frame:
Month 1, 3, 6, 9, 12
Reported as:
Mean · mL/min
Calculated Glomerular Filtration Rate (cGFR) According to Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) at Month 1, 3, 6, 9, 12
mL/minQuadruple Low Level IS RegimenCentre Specific Triple IS Regimen
Month 173.5 ± 13.967.1 ± 12.4
Month 370.4 ± 13.364.3 ± 12.7
Month 669.2 ± 15.563.1 ± 15.0
Month 969.0 ± 16.362.3 ± 14.8
Month 1268.3 ± 16.361.2 ± 14.3
SecondaryCalculated Glomerular Filtration Rate (cGFR) According to Cystatin C-based Hoek's Formula at Month 1, 3, 6, 9, 12

Calculated Glomerular Filtration Rate (cGFR) according to Cystatin C-based Hoek's formula at Month 1, 3, 6, 9, 12

Time frame:
Month 1, 3, 6, 9, 12
Reported as:
Mean · mL/min
Calculated Glomerular Filtration Rate (cGFR) According to Cystatin C-based Hoek's Formula at Month 1, 3, 6, 9, 12
mL/minQuadruple Low Level IS RegimenCentre Specific Triple IS Regimen
Month 168.5 ± 14.661.8 ± 12.8
Month 365.7 ± 15.260.3 ± 10.6
Month 663.0 ± 15.158.7 ± 12.2
Month 961.8 ± 14.157.7 ± 12.8
Month 1260.8 ± 14.257.5 ± 14.1
SecondaryCalculated Glomerular Filtration Rate (cGFR) Using Modification of Diet in Renal Disease (MDRD) Formula at Month 1, 3, 6, 9, 12

Calculated Glomerular Filtration Rate (cGFR) Using Modification of Diet in Renal Disease (MDRD) Formula at Month 1, 3, 6, 9, 12 cGFR (in mL/min/1.73 m2) = 186.3\*(C-1.154)\*(A-0.203)\*G\*R where C = the serum concentration of creatinine (mg/dL), A = age (years), G = 0.742 when gender is female, otherwise G = 1, R = 1.21 when race is black, otherwise R = 1.

Time frame:
Month 1, 3, 6, 9, 12
Reported as:
Mean · mL/min
Calculated Glomerular Filtration Rate (cGFR) Using Modification of Diet in Renal Disease (MDRD) Formula at Month 1, 3, 6, 9, 12
mL/minQuadruple Low Level IS RegimenCentre Specific Triple IS Regimen
Month 172.0 ± 13.565.8 ± 11.8
Month 368.7 ± 12.263.3 ± 12.3
Month 667.6 ± 14.162.3 ± 15.0
Month 967.4 ± 14.961.7 ± 15.1
Month 1267.0 ± 14.860.5 ± 14.4
SecondaryCalculated Glomerular Filtration Rate (cGFR) According to Cockcroft-Gault at Month 1, 3, 6, 9, 12

Calculated Glomerular Filtration Rate (cGFR) according to Cockcroft-Gault at Month 1, 3, 6, 9, 12 For men: GFR=(140-Age) x Body weight (kg) / 72 x Serum Creatinine (mg/dl) For women: GFR=0.85 (140 -Age) x Body weight(kg)/ 72 x Serum Creatinine (mg/dl)

Time frame:
Month 1, 3, 6, 9, 12
Reported as:
Mean · mL/min
Calculated Glomerular Filtration Rate (cGFR) According to Cockcroft-Gault at Month 1, 3, 6, 9, 12
mL/minQuadruple Low Level IS RegimenCentre Specific Triple IS Regimen
Month 178.6 ± 19.272.1 ± 14.9
Month 376.1 ± 17.670.1 ± 16.0
Month 676.2 ± 19.369.1 ± 17.5
Month 976.2 ± 20.169.0 ± 18.2
Month 1276.2 ± 20.668.4 ± 17.8
SecondaryIncidence of Patients Experiencing a Decline in GFR of < 10, 10-15, 15-20, 20-25 and > 25 mL/Min From Baseline to Month 6 and 12.

Incidence of patients experiencing a decline in GFR of \< 10, 10-15, 15-20, 20-25 and \> 25 mL/min from Baseline to Month 6 and 12calculated by the CKD-EPI method. Participants are counted in each decline level observed for that participant; this means participants may be counted in more than 1 decline level.

Time frame:
Baseline, Month 6, Month 12
Reported as:
Number · incidences
Incidence of Patients Experiencing a Decline in GFR of < 10, 10-15, 15-20, 20-25 and > 25 mL/Min From Baseline to Month 6 and 12.
incidencesQuadruple Low Level IS RegimenCentre Specific Triple IS Regimen
Up to Month 6: < 10 mL/min2844
Up to Month 6: 10 - < 15 mL/min918
Up to Month 6: 15 - < 20 mL/min611
Up to Month 6: 20 - < 25 mL/min27
Up to Month 6: > 25 mL/min37
Up to Month 12: < 10 mL/min3653
Up to Month 12: 10 - < 15 mL/min1027
Up to Month 12: 15 - < 20 mL/min818
Up to Month 12: 20 - < 25 mL/min89
Up to Month 12: > 25 mL/min79
SecondaryIncidence of Renal Replacement Therapy at Month 6 and Month 12

Incidence of renal replacement therapy at Month 6 and Month 12: There were no incidences in either group where renal replacement therapy was required

Time frame:
Month 6, Month 12
Reported as:
Number · incidences
Incidence of Renal Replacement Therapy at Month 6 and Month 12
incidencesQuadruple Low Level IS RegimenCentre Specific Triple IS Regimen
up to Month 600
up to Month 1200
SecondaryTime to Renal Replacement Therapy at Month 6 and Month 12

Time to renal replacement therapy at Month 6 and Month 12: There were no incidences in either group where renal replacement therapy was required

Time frame:
Month 6, Month 12

No measurements were reported for this outcome.

SecondaryIncidence of Acute Rejection Episodes at Month 6 and Month 12

Incidence of acute rejection episodes at Month 6 and Month 12. This table counts multiple occurrences of rejection in the same patient as different incidents. Every incident is associated with both an A and a B classification. Classification A: Acute Rejection Grade 0 - none, Grade 1-minimal, Grade 2- mild, Grade 3-moderate, Grade 4-Severe; Classification B: Airway Inflammation-Grade 0-none, Grade 1R-low grade, Grade 2R-high grade, Grade X-ungradeable

Time frame:
Month 6, Month 12
Reported as:
Number · incidences
Incidence of Acute Rejection Episodes at Month 6 and Month 12
incidencesQuadruple Low Level IS RegimenCentre Specific Triple IS Regimen
Up to 6 months: Classification A1113
Up to 6 months: Classification B1113
6 to 12 months: Classification A109
6 to 12 months: Classification B109
SecondaryIncidence of Graft Loss/Re-transplantation at Month 6 and Month 12

Incidence of graft loss/re-transplantation at Month 6 and Month 12

Time frame:
Month 6, Month 12
Reported as:
Number · incidences
Incidence of Graft Loss/Re-transplantation at Month 6 and Month 12
incidencesQuadruple Low Level IS RegimenCentre Specific Triple IS Regimen
Month 600
Month 1211
SecondaryIncidence of Bronchiolitis Obliterans Syndrome (BOS) at Month 6 and Month 12

Incidence of Bronchiolitis obliterans syndrome (BOS) at Month 6 and Month 12 BOS 0 is FEV1 \> 90% of baseline and FEF25-75% \> 75% of baseline; BOS 0-p is FEV1 81-90% of baseline and/or FEF25-75% ≤ 75% of baseline; BOS 1 is FEV1 66-80% of baseline; BOS 2 is FEV1 51-65% of baseline; BOS 3 is FEV1 ≤ 50% of baseline

Time frame:
Month 6, Month 12
Reported as:
Number · incidences
Incidence of Bronchiolitis Obliterans Syndrome (BOS) at Month 6 and Month 12
incidencesQuadruple Low Level IS RegimenCentre Specific Triple IS Regimen
Month 6 - Total (all grades)6661
Month 6 - BOS 03640
Month 6 - BOS 0p2614
Month 6 - BOS 135
Month 6 - BOS 210
Month 6 - BOS 302
Month 6 - BOS (>/=1)47
Month 12 - Total (all grades)6661
Month 12 - BOS 03538
Month 12 - BOS 0p2614
Month 12 - BOS 135
Month 12 - BOS 211
Month 12 - BOS 313
Month 12 - BOS (>/=1)59
SecondaryIncidence of Death at Month 6 and Month 12

Incidence of death at Month 6 and Month 12

Time frame:
Month 6, Month 12
Reported as:
Number · incidences
Incidence of Death at Month 6 and Month 12
incidencesQuadruple Low Level IS RegimenCentre Specific Triple IS Regimen
Month 600
Month 1231
SecondaryQuality of Life (QoL, SF36) at Month 6 and Month 12

Quality of Life (QoL, SF36) at Month 6 and Month 12 Scores can range from a minimum of 0 (maximum disability) to a maximum of 100 (no disability).

Time frame:
Month 6, Month 12
Reported as:
Mean · scores on a scale
Quality of Life (QoL, SF36) at Month 6 and Month 12
scores on a scaleQuadruple Low Level IS RegimenCentre Specific Triple IS Regimen
Month 6: Physical component summary score46.9 ± 7.648.9 ± 7.3
Month 6: Mental component summary score51.5 ± 10.852.6 ± 8.1
Month 6: Physical functioning78.8 ± 20.984.1 ± 16.8
Month 6: Role-Physical71.1 ± 23.277.1 ± 24.2
Month 6: Bodily pain76.4 ± 27.981.3 ± 23.4
Month 6: General health perception65.4 ± 19.270.6 ± 19.9
Month 6: Vitality67.4 ± 18.070.0 ± 14.6
Month 6:Social functioning84.1 ± 22.688.9 ± 17.6
Month 6: Role-Emotional84.7 ± 22.484.8 ± 17.9
Month 6: Mental health78.5 ± 17.281.0 ± 12.8
Month 12: Physical component summary score47.2 ± 8.847.7 ± 7.1
Month 12: Mental component summary score49.7 ± 11.853.8 ± 9.1
Month 12: Physical functioning77.4 ± 21.882.5 ± 20.0
Month 12: Role-Physical68.3 ± 26.878.0 ± 22.9
Month 12: Bodily Pain76.8 ± 27.080.1 ± 22.7
Month 12: General health perception66.7 ± 17.365.8 ± 20.3
Month 12: Vitality65.7 ± 19.469.9 ± 17.5
Month 12: Social functioning82.3 ± 23.090.5 ± 16.1
Month 12: Role-Emotional79.4 ± 27.386.2 ± 20.5
Month 12: Mental health75.4 ± 18.281.8 ± 14.8
SecondaryExercise Capacity 6-Minute Walk Test(6MWT) at Month 6 and Month 12

Exercise capacity (6MWT) at Month 6 and Month 12 Measured by the Borg Scale. THE BORG SCALE 0 is Nothing at all, 0.5 is Very, very slight (just noticeable); 1 is Very slight, 2 is Slight (light); 3 is Moderate; 4 is Somewhat severe; 5 is Severe (heavy), 7 is Very severe, 10 is Very, very severe (maximal)The higher the Borg score implies increased shortness of breath and/or increased fatigue.

Time frame:
Month 6, Month 12
Reported as:
Mean · Scores on a scale
Exercise Capacity 6-Minute Walk Test(6MWT) at Month 6 and Month 12
Scores on a scaleQuadruple Low Level IS RegimenCentre Specific Triple IS Regimen
Month 6-Borg score - Before start of test0.47 ± 0.780.39 ± 0.77
Month 6-Borg score - At end of test1.75 ± 1.581.64 ± 1.31
Month 12-Borg score - Before start of test0.38 ± 0.940.42 ± 0.79
Month 12-Borg score - At end of test2.08 ± 1.582.06 ± 1.85
SecondaryIncidence of Treated Arterial Hypertension up to Month 12

Incidence of treated of arterial hypertension up to Month 12

Time frame:
up to Month 12
Reported as:
Number · incidences
Incidence of Treated Arterial Hypertension up to Month 12
incidencesQuadruple Low Level IS RegimenCentre Specific Triple IS Regimen
Month 121
Month 321
Month 621
Month 931
Month 1241
SecondaryIncidence of Diabetes Mellitus up to Month 12

Incidence of Diabetes Mellitus up to Month 12

Time frame:
up to Month 12
Reported as:
Number · incidences
Incidence of Diabetes Mellitus up to Month 12
incidencesQuadruple Low Level IS RegimenCentre Specific Triple IS Regimen
Month 100
Month 300
Month 601
Month 911
Month 1211
SecondaryTrough Levels of Everolimus at Month 1, 3, 6, 9, 12

Trough levels of everolimus at Month 1, 3, 6, 9, 12

Time frame:
Month 1, 3, 6, 9, 12
Reported as:
Mean · ng/mL
Trough Levels of Everolimus at Month 1, 3, 6, 9, 12
ng/mLQuadruple Low Level IS Regimen
Month 14.2 ± 1.4
Month 34.4 ± 1.2
Month 64.1 ± 1.2
Month 94.5 ± 1.6
Month 124.3 ± 1.1
SecondaryAdherence to Target Ranges of Everolimus at Month 1, 3, 6, 9, 12

Adherence to target ranges of everolimus at Month 1, 3, 6, 9, 12

Time frame:
Month 1, 3, 6, 9, 12
Reported as:
Number · participant adherence
Adherence to Target Ranges of Everolimus at Month 1, 3, 6, 9, 12
participant adherenceQuadruple Low Level IS Regimen
Month 1 Below Target Range10 ± 1.4
Month 1 Within Target Range42 ± 1.2
Month 1 Above Target Range14 ± 1.2
Month 3 Below Target Range5 ± 1.6
Month 3 Within Target Range41 ± 1.1
Month 3 Above Target Range15
Month 6 Below Target Range7
Month 6 Within Target Range39
Month 6 Above Target Range12
Month 9 Below Target Range5
Month 9 Within Target Range34
Month 9 Above Target Range13
Month 12 Below Target Range3
Month 12 Within Target Range38
Month 12 Above Target Range9
SecondaryTrough Levels of Cyclosporine A (CsA) at Month 1, 3, 6, 9, 12

Trough levels of Cyclosporine A (CsA) at Month 1, 3, 6, 9, 12

Time frame:
Month 1, 3, 6, 9, 12
Reported as:
Mean · ng/mL
Trough Levels of Cyclosporine A (CsA) at Month 1, 3, 6, 9, 12
ng/mLQuadruple Low Level IS RegimenCentre Specific Triple IS Regimen
Month 161 ± 21.83106 ± 21.25
Month 359.65 ± 20.43109 ± 24.95
Month 658.50 ± 12.84103 ± 32.95
Month 957.59 ± 23.26107 ± 29.13
Month 1269.33 ± 48.41108 ± 27.82
SecondaryAdherence to Target Ranges of Cyclosporine A (CsA) at Month 1, 3, 6, 9, 12

Adherence to target ranges of Cyclosporine A (CsA) at Month 1, 3, 6, 9, 12

Time frame:
Month 1, 3, 6, 9, 12
Reported as:
Number · participant adherence
Adherence to Target Ranges of Cyclosporine A (CsA) at Month 1, 3, 6, 9, 12
participant adherenceQuadruple Low Level IS RegimenCentre Specific Triple IS Regimen
Month 1 Below Target Range0 ± 21.838 ± 21.25
Month 1 Within Target Range18 ± 20.438 ± 24.95
Month 1 Above Target Range3 ± 12.840 ± 32.95
Month 3 Below Target Range0 ± 23.264 ± 29.13
Month 3 Within Target Range18 ± 48.4110 ± 27.82
Month 3 Above Target Range20
Month 6 Below Target Range06
Month 6 Within Target Range188
Month 6 Above Target Range20
Month 9 Below Target Range04
Month 9 Within Target Range169
Month 9 Above Target Range10
Month 12 Below Target Range03
Month 12 Within Target Range1610
Month 12 Above Target Range50
SecondaryTrough Levels of Tacrolimus at Month 1, 3, 6, 9, 12

Trough levels of Tacrolimus at Month 1, 3, 6, 9, 12

Time frame:
Month 1, 3, 6, 9, 12
Reported as:
Mean · ng/mL
Trough Levels of Tacrolimus at Month 1, 3, 6, 9, 12
ng/mLQuadruple Low Level IS RegimenCentre Specific Triple IS Regimen
Month 15.07 ± 1.8010.44 ± 2.73
Month 35.18 ± 2.0210.53 ± 2.88
Month 64.70 ± 1.9810.09 ± 3.37
Month 95.78 ± 4.1810.67 ± 3.44
Month 125.19 ± 2.369.66 ± 3.01
SecondaryAdherence to Target Ranges of Tacrolimus at Month 1, 3, 6, 9, 12

Adherence to target ranges of Tacrolimus at Month 1, 3, 6, 9, 12

Time frame:
Month 1, 3, 6, 9, 12
Reported as:
Number · participant adherence
Adherence to Target Ranges of Tacrolimus at Month 1, 3, 6, 9, 12
participant adherenceQuadruple Low Level IS RegimenCentre Specific Triple IS Regimen
Month 1 Below Target Range3 ± 21.830 ± 21.25
Month 1 Within Target Range24 ± 20.4345 ± 24.95
Month 1 Above Target Range17 ± 12.840 ± 32.95
Month 3 Below Target Range3 ± 23.260 ± 29.13
Month 3 Within Target Range23 ± 48.4147 ± 27.82
Month 3 Above Target Range180
Month 6 Below Target Range51
Month 6 Within Target Range2345
Month 6 Above Target Range120
Month 9 Below Target Range20
Month 9 Within Target Range1846
Month 9 Above Target Range180
Month 12 Below Target Range30
Month 12 Within Target Range2347
Month 12 Above Target Range150
SecondaryIncidence of Bacterial, Viral, and Fungal Infections at Month 12

Incidence of bacterial, viral, and fungal infections at Month 12

Time frame:
Month 12
Reported as:
Number · incidences
Incidence of Bacterial, Viral, and Fungal Infections at Month 12
incidencesQuadruple Low Level IS RegimenCentre Specific Triple IS Regimen
Bacterial infections34
Viral infections1420
Fungal infections30
SecondaryTriglyceride Levels at Month 1, 3, 6, 9, 12

Triglyceride levels at Month 1, 3, 6, 9, 12

Time frame:
Month 1, 3, 6, 9, 12
Reported as:
Mean · mmol/L
Triglyceride Levels at Month 1, 3, 6, 9, 12
mmol/LQuadruple Low Level IS RegimenCentre Specific Triple IS Regimen
Month 12.6 ± 1.42.0 ± 0.9
Month 32.7 ± 1.32.1 ± 1.0
Month 62.6 ± 1.22.0 ± 1.1
Month 92.7 ± 1.32.0 ± 1.0
Month 122.7 ± 1.52.1 ± 0.9
SecondaryTotal Cholesterol Levels at Month 1, 3, 6, 9, 12

Total Cholesterol levels at Month 1, 3, 6, 9, 12

Time frame:
Month 1, 3, 6, 9, 12
Reported as:
Mean · mmol/L
Total Cholesterol Levels at Month 1, 3, 6, 9, 12
mmol/LQuadruple Low Level IS RegimenCentre Specific Triple IS Regimen
Month 10.8 ± 0.8-0.2 ± 0.7
Month 31.0 ± 0.8-0.1 ± 0.9
Month 61.1 ± 0.9-0.2 ± 0.8
Month 91.1 ± 0.9-0.1 ± 0.9
Month 120.8 ± 1.1-0.1 ± 0.8
SecondaryLow-Density Lipoprotein (LDL)Cholesterol Levels at Month 1, 3, 6, 9, 12

LDL Cholesterol levels at Month 1, 3, 6, 9, 12

Time frame:
Month 1, 3, 6, 9, 12
Reported as:
Mean · mmol/L
Low-Density Lipoprotein (LDL)Cholesterol Levels at Month 1, 3, 6, 9, 12
mmol/LQuadruple Low Level IS RegimenCentre Specific Triple IS Regimen
Month 10.4 ± 0.80.0 ± 0.5
Month 30.6 ± 0.7-0.0 ± 0.6
Month 60.7 ± 0.8-0.0 ± 0.6
Month 90.8 ± 0.80.1 ± 0.7
Month 120.5 ± 0.90.1 ± 0.6
SecondaryHigh-Density Lipoprotein (HDL)Cholesterol Levels at Month 1, 3, 6, 9, 12

HDL Cholesterol levels at Month 1, 3, 6, 9, 12

Time frame:
Month 1, 3, 6, 9, 12
Reported as:
Mean · mmol/L
High-Density Lipoprotein (HDL)Cholesterol Levels at Month 1, 3, 6, 9, 12
mmol/LQuadruple Low Level IS RegimenCentre Specific Triple IS Regimen
Month 10.1 ± 0.3-0.1 ± 0.3
Month 30.1 ± 0.3-0.0 ± 0.4
Month 60.1 ± 0.4-0.0 ± 0.4
Month 90.0 ± 0.4-0.0 ± 0.4
Month 120.0 ± 0.5-0.0 ± 0.4

Adverse events

Collected over Adverse events are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All adverse events reported in this record are from date of First Patient First Treatment until 12 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Quadruple Low Level IS Regimen—29/67 (43.3%)62/67 (92.5%)
Centre Specific Triple IS Regimen—22/63 (34.9%)58/63 (92.1%)
Most frequent serious events
Showing 10 of 89
Most frequent serious events
EventQuadruple Low Level IS RegimenCentre Specific Triple IS Regimen
FORCED EXPIRATORY VOLUME DECREASEDInvestigations9/675/63
LUNG TRANSPLANT REJECTIONImmune system disorders5/670/63
CYTOMEGALOVIRUS INFECTIONInfections and infestations1/674/63
DYSPNOEARespiratory, thoracic and mediastinal disorders3/674/63
PYREXIAGeneral disorders4/673/63
PNEUMONIAInfections and infestations3/673/63
RESPIRATORY TRACT INFECTIONInfections and infestations1/673/63
CHEST PAINGeneral disorders3/670/63
OEDEMA PERIPHERALGeneral disorders3/670/63
INFECTIONInfections and infestations3/672/63
Most frequent other events
Showing 10 of 28
Most frequent other events
EventQuadruple Low Level IS RegimenCentre Specific Triple IS Regimen
LEUKOPENIABlood and lymphatic system disorders15/6719/63
OEDEMA PERIPHERALGeneral disorders19/6710/63
NASOPHARYNGITISInfections and infestations17/6717/63
ACNESkin and subcutaneous tissue disorders12/671/63
CYTOMEGALOVIRUS INFECTIONInfections and infestations10/6711/63
DIARRHOEAGastrointestinal disorders9/6710/63
NAUSEAGastrointestinal disorders9/6710/63
COUGHRespiratory, thoracic and mediastinal disorders10/677/63
HEADACHENervous system disorders8/679/63
FORCED EXPIRATORY VOLUME DECREASEDInvestigations7/678/63

Baseline characteristics

Age, Continuous
Age, Continuous(years)Quadruple Low Level IS RegimenCentre Specific Triple IS RegimenTotal
Mean53.9 ± 9.554.2 ± 9.254.0 ± 9.3
Sex: Female, Male
Sex: Female, Male(Participants)Quadruple Low Level IS RegimenCentre Specific Triple IS RegimenTotal
Female272249
Male404181
08

Study locations

9 sites
  • Novartis Investigative Site
    Berlin, 10117, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Essen, 45147, Germany
  • Novartis Investigative Site
    Freiburg, 79106, Germany
  • Novartis Investigative Site
    Hamburg, 20246, Germany
  • Novartis Investigative Site
    Hannover, 30625, Germany
  • Novartis Investigative Site
    Homburg, 66421, Germany
  • Novartis Investigative Site
    Leipzig, 04103, Germany
  • Novartis Investigative Site
    Muenchen, 81377, Germany
09

References and documents

Publications

  • Kneidinger N, Valtin C, Hettich I, Frye BC, Wald A, Wilkens H, Bessa V, Gottlieb J. Five-year Outcome of an Early Everolimus-based Quadruple Immunosuppression in Lung Transplant Recipients: Follow-up of the 4EVERLUNG Study. Transplantation. 2022 Sep 1;106(9):1867-1874. doi: 10.1097/TP.0000000000004095. Epub 2022 Mar 8. PubMed 35283454 ↗
  • Gottlieb J, Neurohr C, Muller-Quernheim J, Wirtz H, Sill B, Wilkens H, Bessa V, Knosalla C, Porstner M, Capusan C, Struber M. A randomized trial of everolimus-based quadruple therapy vs standard triple therapy early after lung transplantation. Am J Transplant. 2019 Jun;19(6):1759-1769. doi: 10.1111/ajt.15251. Epub 2019 Feb 5. PubMed 30615259 ↗

Individual participant data

Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2012 to primary completion in Jan 2017, 59 months.

Results were first posted in Mar 2019, 2 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2011
First posted
Jul 28, 2011
StartActual
Feb 1, 2012
Primary completionActual
Jan 5, 2017
CompletionActual
Jan 5, 2017
Results first posted
Mar 14, 2019
Last update
Mar 14, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 14, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01404325
Responsible party
Sponsor
First posted
Jul 28, 2011
Start date
Feb 1, 2012
Primary completion
Jan 5, 2017
Completion
Jan 5, 2017
Results posted
Mar 14, 2019
Last update
Mar 14, 2019

Study contacts

Novartis Pharmceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Everolimus

Start the discussion